These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 34208001)

  • 1. Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells.
    Shrestha R; Bridle KR; Cao L; Crawford DHG; Jayachandran A
    Curr Oncol; 2021 Jun; 28(3):2150-2172. PubMed ID: 34208001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.
    Shrestha R; Prithviraj P; Bridle KR; Crawford DHG; Jayachandran A
    J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33925488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-
    Shrestha R; Bridle KR; Crawford DHG; Jayachandran A
    Int J Med Sci; 2021; 18(12):2466-2479. PubMed ID: 34104078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death ligand 1 regulates epithelial-mesenchymal transition and cancer stem cell phenotypes in hepatocellular carcinoma through the serum and glucocorticoid kinase 2/β-catenin signaling pathway.
    Kong X; Peng H; Liu P; Fu X; Wang N; Zhang D
    Cancer Sci; 2023 Jun; 114(6):2265-2276. PubMed ID: 36751987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma.
    Shrestha R; Bridle KR; Crawford DHG; Jayachandran A
    Mol Med Rep; 2020 Apr; 21(4):1849-1860. PubMed ID: 32319631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib.
    Yamada T; Abei M; Danjoh I; Shirota R; Yamashita T; Hyodo I; Nakamura Y
    BMC Cancer; 2015 Apr; 15():260. PubMed ID: 25885470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
    Bort A; Sánchez BG; Mateos-Gómez PA; Vara-Ciruelos D; Rodríguez-Henche N; Díaz-Laviada I
    Mol Oncol; 2019 May; 13(5):1311-1331. PubMed ID: 30959553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
    Nagai T; Arao T; Furuta K; Sakai K; Kudo K; Kaneda H; Tamura D; Aomatsu K; Kimura H; Fujita Y; Matsumoto K; Saijo N; Kudo M; Nishio K
    Mol Cancer Ther; 2011 Jan; 10(1):169-77. PubMed ID: 21220499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA THOR promotes liver cancer stem cells expansion via β-catenin pathway.
    Cheng Z; Lei Z; Yang P; Si A; Xiang D; Zhou J; Hüser N
    Gene; 2019 Feb; 684():95-103. PubMed ID: 30359743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABI2-mediated MEOX2/KLF4-NANOG axis promotes liver cancer stem cell and drives tumour recurrence.
    Chen J; Li H; Zhang B; Xiong Z; Jin Z; Chen J; Zheng Y; Zhu X; Zhang S
    Liver Int; 2022 Nov; 42(11):2562-2576. PubMed ID: 36017822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HBx Modulates Drug Resistance of Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Liu Y; Liu X; Luo M; Li Y; Li H
    Discov Med; 2023 Dec; 35(179):1035-1042. PubMed ID: 38058068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
    Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway.
    Li B; Liu D; Yang P; Li HY; Wang D
    Gene; 2019 Jul; 707():78-85. PubMed ID: 31075412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
    Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
    Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspase-3-Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma.
    Mok EHK; Leung CON; Zhou L; Lei MML; Leung HW; Tong M; Wong TL; Lau EYT; Ng IOL; Ding J; Yun JP; Yu J; Zhu HL; Lin CH; Lindholm D; Leung KS; Cybulski JD; Baker DM; Ma S; Lee TKW
    Cancer Res; 2022 Sep; 82(17):3102-3115. PubMed ID: 35767704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
    Liu J; Liu Y; Meng L; Liu K; Ji B
    Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells.
    Cho S; Kim W; Yoo D; Han Y; Hwang H; Kim S; Kim J; Park S; Park Y; Jo H; Pyun JC; Lee M
    Sci Rep; 2024 Jan; 14(1):1751. PubMed ID: 38243049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.